Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi, Fukuoka 812-8582, Japan.
CNS Neurol Disord Drug Targets. 2012 Sep;11(6):699-704. doi: 10.2174/187152712803581065.
We have learned various data on the role of purinoceptors (P2X4, P2X7, P2Y6 and P2Y12 receptors) expressed in spinal microglia and several factors that presumably activate microglia in neuropathic pain after peripheral nerve injury. Especially P2X4 receptors (P2X4Rs) make a critical contribution to the pain processing. P2X4Rs of microglia might be promising targets for treating neuropathic pain. A predicted therapeutic benefit of interfering with microglial P2X4Rs may be that normal pain sensitivity would be unaffected since expression or activity of most of these receptors are upregulated or enhanced predominantly in activated microglia in the spinal cord where damaged sensory fibers project. Recently, we found that CCL21 regulates the expression of P2X4Rs in different manners, respectively. These new findings also provide novel targets for developing anti-neuropathic pain medicines.
我们已经了解了在脊髓小胶质细胞中表达的嘌呤能受体(P2X4、P2X7、P2Y6 和 P2Y12 受体)以及外周神经损伤后神经病理性疼痛中小胶质细胞可能被激活的几种因素的相关数据。特别是 P2X4 受体(P2X4Rs)对疼痛处理有重要贡献。小胶质细胞的 P2X4Rs 可能是治疗神经病理性疼痛的有前途的靶点。干扰小胶质细胞 P2X4Rs 的预期治疗益处可能是,由于这些受体中的大多数在外周神经损伤后主要在脊髓中受损感觉纤维投射的激活的小胶质细胞中上调或增强,因此正常的疼痛敏感性不受影响。最近,我们发现 CCL21 以不同的方式分别调节 P2X4Rs 的表达。这些新发现也为开发抗神经病理性疼痛药物提供了新的靶点。